8-K: Theravance Biopharma Highlights Pipeline Progress and Financial Outlook at H.C. Wainwright Conference

Theravance Biopharma presented an investor update, highlighting progress with YUPELRI and ampreloxetine, along with financial guidance and potential milestones.

Summary

• Theravance Biopharma is focused on respiratory and neurology therapeutics, with key assets including YUPELRI for COPD and ampreloxetine for neurogenic orthostatic hypotension (nOH) in Multiple System Atrophy (MSA).
• YUPELRI, a once-daily nebulized LAMA for COPD, has seen US net sales reach $229 million in the last twelve months, with Theravance receiving 35% of US profits.
• The company anticipates potential milestones of up to $150 million for YUPELRI in the US and $45 million in China, along with tiered royalties of 14-20% in China.
• Ampreloxetine, a potential first-in-class therapy for nOH in MSA, is in a pivotal Phase 3 study (CYPRESS) with last patient enrollment expected in mid-2025 and data readout approximately six months later.
• Theravance is also eligible for up to $200 million in TRELEGY sales milestones from 2024 to 2026, and royalties on global TRELEGY sales from 2029 through the mid-2030s.
• The company reported a GAAP net loss from operations of $15.7 million for Q2 2024, and a non-GAAP net loss from operations of $6.3 million.
• Theravance has $96.1 million in cash and no debt as of the end of Q2 2024.
• The company expects a non-GAAP loss and cash burn in the second half of 2024 similar to the first half, excluding potential milestones.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in key programs and a solid financial position, but also acknowledges ongoing losses and risks. The potential for future milestones and royalties is encouraging.

Positives

• YUPELRI is a profitable brand with expanding profit margins and significant growth potential in the US and China.
• Ampreloxetine has shown durable, clinically significant symptom improvements in MSA patients with nOH.
• The company has strong patent protection for YUPELRI and ampreloxetine, extending into the late 2030s.
• Theravance has a strong cash position with no debt, providing financial stability.
• The company has a clear path to potential regulatory approval for ampreloxetine, with FDA alignment on the CYPRESS trial design.
• The partnership with Viatris is driving YUPELRI prescription growth.
• The company has a focused strategy on respiratory and neurology indications with high unmet needs.

Negatives

• The company reported a GAAP net loss from operations of $15.7 million for Q2 2024.
• The company's non-GAAP net loss from operations was $6.3 million in Q2 2024.
• The company anticipates a non-GAAP loss and cash burn in the second half of 2024 similar to the first half.
• The company's operating expenses are significant, with R&D and SG&A costs totaling $22.4 million in Q2 2024 excluding share-based compensation.

Risks

• The company's future profitability is subject to risks related to clinical trial outcomes, regulatory approvals, and commercialization success.
• There are risks associated with dependence on third parties for clinical studies, manufacturing, and commercialization.
• The company faces competition from other pharmaceutical companies in the respiratory and neurology markets.
• The company's financial performance is subject to fluctuations in the trading price and volume of its shares.
• There are risks associated with achieving the TRELEGY sales milestones and royalty payments.
• The company's non-GAAP financial measures may not be comparable to those of other companies.

Future Outlook

The company expects a non-GAAP loss and cash burn in the second half of 2024 similar to the first half, excluding potential milestones. They anticipate potential milestones for YUPELRI in the US and China, and are progressing the CYPRESS study for ampreloxetine.

Management Comments

• Management is focused on growing YUPELRI and addressing the significant problem of nOH in MSA.
• Management believes ampreloxetine may be uniquely tailored to mitigate symptoms of nOH and improve quality of life.
• Management highlights the company's strong cash position and potential for future royalties from TRELEGY.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly in the respiratory and neurology therapeutic areas. The company's focus on unmet needs in COPD and MSA aligns with broader industry trends towards developing treatments for chronic and debilitating conditions. The partnership with Viatris and the economic interest in GSK's TRELEGY are also common strategies in the pharmaceutical sector.

Comparison to Industry Standards

• Theravance's YUPELRI competes with other long-acting muscarinic antagonists (LAMAs) for COPD, such as those from Boehringer Ingelheim (Spiriva) and AstraZeneca (Eklira). However, YUPELRI is unique as a once-daily nebulized LAMA.
• The development of ampreloxetine for nOH in MSA is novel, as there are currently limited effective treatments for this condition. Other companies, such as Lundbeck (Northera), offer treatments for orthostatic hypotension, but these are not specifically targeted for MSA.
• The TRELEGY royalty structure is similar to other pharmaceutical royalty agreements, where a company sells rights to future royalties but retains a portion of the economic benefit. Royalty Pharma is a common player in this space.
• The company's financial performance is comparable to other biotech companies in the clinical stage, with a focus on managing cash burn and achieving key milestones.

Stakeholder Impact

• Shareholders may benefit from the potential for future revenue growth and milestones.
• Employees are likely to be impacted by the company's strategic focus and operational decisions.
• Patients with COPD and MSA may benefit from the development of new treatment options.
• Viatris and GSK are key partners and will be impacted by the success of YUPELRI and TRELEGY.

Next Steps

• The company will continue to commercialize YUPELRI in the US and pursue regulatory approval in China.
• The company will focus on completing the CYPRESS study for ampreloxetine and preparing for regulatory filings.
• The company will monitor TRELEGY sales and work towards achieving the sales milestones.
• The company will manage its operating expenses and cash burn.

Key Dates

Keywords

Theravance Biopharma, YUPELRI, Ampreloxetine, COPD, MSA, nOH, TRELEGY, Respiratory, Neurology, Milestones, Royalties, Clinical Trials, FDA, Pharmaceuticals